"Study Title","Study Abbreviation","Authors","Published in","Date Published","Number of Randomized Patients","Conclusion","Primary Outcome","Results for the Primary Outcome","Blinding","Comparator","Link to Article"
"
              
                Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
              
            ","Austrian Breast and Colorectal Cancer Study Group","Gnant, Michael et al.","NEJM","2021/07/28","3484","Extending hormone therapy by 5 years provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture.","Disease-free survival","Disease progression or death occurred in 335 women in each treatment group in the primary-analysis set at 8 years (hazard ratio, 0.99; 95% CI, 0.85 to 1.15; P = 0.90).","Not stated","2-year group and 5-year group","https://pubmed.ncbi.nlm.nih.gov/34320285/?format=pubmed",
"
              
                21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
              
            ","NA","Kalinsky, Kevin et al.","NEJM","2021/12/16","5083","Error","Invasive disease-free survival","Among postmenopausal women, invasive disease-free survival at 5 years was 91.9% in the endocrine-only group and 91.3% in the chemoendocrine group, with no chemotherapy benefit (hazard ratio for invasive disease recurrence, new primary cancer [breast cancer or another type], or death, 1.02; 95% confidence interval [CI], 0.82 to 1.26; P = 0.89). Among premenopausal women, invasive disease-free survival at 5 years was 89.0% with endocrine-only therapy and 93.9% with chemoendocrine therapy (hazard ratio, 0.60; 95% CI, 0.43 to 0.83; P = 0.002), with a similar increase in distant relapse-free survival (hazard ratio, 0.58; 95% CI, 0.39 to 0.87; P = 0","Not specified","Endocrine therapy only vs. chemotherapy plus endocrine therapy","https://pubmed.ncbi.nlm.nih.gov/34914339/?format=pubmed",
"
              
                A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
              
            ","FLAIR","Bergenstal, Richard M et al.","Lancet","2021/01/17","113","Error","Proportion of time that glucose levels were above 180 mg/dL (>10*0 mmol/L) during 0600 h to 2359 h (ie, daytime) and proportion of time that glucose levels were below 54 mg/dL (<3*0 mmol/L) calculated over a full 24-h period","Mean proportion of time with daytime glucose levels above 180 mg/dL (>10*0 mmol/L) was 42% (SD 13) at baseline, 37% (9) during use of the 670G system, and 34% (9) during use of the advanced hybrid closed-loop system (mean difference [advanced hybrid closed-loop system minus 670G system] -3*00% [95% CI -3*97 to -2*04]; p<0*0001). Mean 24-h proportion of time with glucose levels below 54 mg/dL (<3*0 mmol","Not possible due to the nature of the systems used","MiniMed 670G hybrid closed-loop system (670G) vs. investigational advanced hybrid closed-loop system (Medtronic)","https://pubmed.ncbi.nlm.nih.gov/33453783/?format=pubmed",
